



NeuroEM Therapeutic's CEO provides keynote address at Australian conference on biologic effects of electromagnetic exposure

Phoenix, AZ (November 23rd, 2016) The CEO and President of NeuroEM Therapeutics, Inc., Dr. Gary Arendash, was the keynote speaker at Australia's 2016 Science and Wireless conference. The conference was sponsored by the Australian Center for Electromagnetic Bioeffects Research (ACEBR) and was held on November 22nd at the Royal Melbourne Institute of Technology.

"It is a real honor to have been ask to do this presentation" said Dr. Arendash. "The ACEBR is a stellar group of researchers from multiple scientific disciplines and Australian universities who have been brought together as a national center of research excellence. Their purpose is to explore the biologic effects of electromagnetic waves, especially in the radiofrequency range".

In his presentation, Dr. Arendash discussed the reasons why drugs continue to fail in Alzheimer's clinical trials and why NeuroEM's electromagnetic technology should be safe and could be effective in stabilizing or reversing the memory loss of Alzheimer's Disease. He also provided information on NeuroEM's on-going Phase I clinical trial in Alzheimer's patients. The trial is testing the safety and initial efficacy of the company's first-in-class head device, which emits electromagnetic waves that are hoped to improve memory of Alzheimer's patients.

Most of us are exposed to electromagnetic waves every day, particularly in the radiofrequency range utilized by mobile phones. NeuroEM's head device exposes the entire human brain to such radiofrequency waves. Although a few early epidemiological studies suggested that radiofrequency waves may have deleterious health effects (such as increased risk of brain cancer), larger and more recent epidemiologic studies clearly find no deleterious health effects of radiofrequency wave exposure.

In fact, beneficial effects of electromagnetic wave treatment are starting to be reported. Along this line, Dr. Arendash and colleagues found that long-term radiofrequency wave treatment to Alzheimer's mice reverses their memory impairment – apparently through several disease-modifying mechanisms. As well, radiofrequency waves have consistently been shown to enhance alpha wave activity in human EEG recordings. Alpha waves are important for basic cognitive processing.

"The ACEBR impartially investigates many aspects of electromagnetic effects on humans" said Dr. Arendash. "I look forward to their continued efforts, especially in exploring potential beneficial effects of electromagnetic waves on human health".

About NeuroEM Therapeutics, Inc.

NeuroEM Therapeutics is a medical device company focused on development of Transcranial Electromagnetic Treatment (TEMT) to treat neurodegenerative disorders such as Alzheimer's Disease, Traumatic Brain Injury, and Down's Syndrome. The company is headquartered in Phoenix, AZ, which is a

hub of both pre-clinical and clinical investigation into neurodegenerative disorders and diseases. As such, NeuroEM Therapeutics is collaborating with leading institutions in the Phoenix area such as Banner Sun Health Research Institute, Banner Alzheimer's Institute, and Arizona State University. For more information about NeuroEM Therapeutics, go to www.neuroem.com.

Forward-Looking Statements

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of NeuroEM Therapeutics, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.